Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Time to Sell?

by · The Markets Daily

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report)’s stock price gapped down before the market opened on Monday . The stock had previously closed at $9.44, but opened at $8.84. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.90, with a volume of 66,592 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a report on Wednesday, April 8th. Two analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock has an average rating of “Hold”.

Get Our Latest Report on SGIOY

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The company has a 50 day moving average price of $10.14 and a 200-day moving average price of $9.88. The company has a market cap of $15.08 billion, a price-to-earnings ratio of 11.08, a P/E/G ratio of 3.58 and a beta of 0.08. The company has a quick ratio of 5.21, a current ratio of 5.84 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.03. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.09% and a net margin of 41.08%.The company had revenue of $881.71 million during the quarter, compared to analysts’ expectations of $895.52 million. As a group, equities research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 EPS for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

(Get Free Report)

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.

Recommended Stories